- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01943864
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
A Phase IIa Study of the MEK Inhibitor GSK1120212 Monotherapy in the Treatment of Gemcitabine Refractory Locally Advanced, Recurrent or Metastatic Biliary Tract Cancers
This is a Phase IIa, open-label, single-arm, multi-center study to evaluate the efficacy and safety of orally administered MEK inhibitor trametinib as the second line in subjects with advanced or metastatic biliary tract cancers (BTC) in Japanese population. The primary endpoint of this study is 12 week non-progressive disease (PD) rate defined as the percentage of subjects without progression at Week 12. As a sub-study, pharmacokinetics (PK) of four tablets of 0.5 milligram (mg) tablet, or one tablet of 2 mg tablet to achieve 2 mg daily regimen will be assessed to evaluate the pharmacokinetics of trametinib in Japanese population.
Eligible subjects will be randomized to receive trametinib at the recommended Phase II dose of 2 mg every day as one 2 mg tablet or four 0.5 mg tablets on Day 1. From Day 2 until disease progression or withdrawal from the study treatment, all subjects will receive one tablet of 2 mg trametinib . Disease assessment will be performed every 8 week. Translational research is also planned to evaluate the potential blood or tumor tissue-derived biomarkers for biological activity, and sensitivity or resistance to treatment with trametinib .
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Chiba, Japan, 277-8577
- GSK Investigational Site
-
Osaka, Japan, 537-8511
- GSK Investigational Site
-
Shizuoka, Japan, 411-8777
- GSK Investigational Site
-
Tokyo, Japan, 104-0045
- GSK Investigational Site
-
Tokyo, Japan, 181-8611
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female of age 20 years or older inclusive, at the time of signing the informed consent.
- Japanese patients with histologically or cytologically confirmed cholangiocarcinoma (intra- or extrahepatic) or gallbladder cancer or ampulla of Vater cancer are eligible for which all of the following criteria have to be met: Nonresectable, recurrent, and/or metastatic disease.
- Disease progression after up to two lines of systemic chemotherapies including no more than one line of gemcitabine-based chemotherapy. Note: Systemic therapy in adjuvant setting is not allowed as prior therapy.
- More than 21 days have elapsed since any prior anti-tumor therapy.
- At least one of the tumor samples for archived tissue at initial diagnosis or archived tissue at recent progression or fresh biopsy at recent progression (collect within 21 days from randomization if none of the archived tissues are available) is available prior to randomization to provide for translational research.
- Measurable disease, i.e. presenting with at least one measurable lesion per the RESIST 1.1.
- Performance status score of ≤1 according to the Eastern Cooperative Oncology Group (ECOG) scale.
- Estimated life expectancy of at least 12 weeks.
- All prior treatment- related toxicities must be common terminology criteria for adverse events (CTCAE) (Version 4.0) ≤ Grade 1 (except alopecia) at the time of randomization.
- Negative for hepatitis C virus (HCV) test, hepatitis B surface (HBs) antigen, hepatitis virus Bc (HBc) antibody, and HBs antibody. HBs antigen-negative subjects who test positive for both HBc antibody and HBs antibody or either of them may be eligible when their HBV DNA quantification result is negative.
- Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
- Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment and agree to use effective contraception throughout the treatment period, and for 4 months after the last dose of study treatment.
- Adequate baseline organ function for haematological, hepatic, renal, cardiac systems.
Exclusion Criteria:
- History of another malignancy.
- Any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures.
- Radiotherapy completed within 2 weeks prior to randomization.
- History of interstitial lung disease or pneumonitis.
- Having a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO).
- Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 28 days prior to randomization and/or chemotherapy without the potential for delayed toxicity within 21days prior to randomization.
- Any prior use of any MEK inhibitors (including but not limited to trametinib, AZD6244 (selumetinib), RDEA119).
- Current use of a prohibited medication.
- History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR).
- Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression.
- Known Human Immunodeficiency Virus (HIV) infection. History or evidence of cardiovascular risk including a QT interval corrected for heart rate using the Bazett's formula (QTcB) interval >480 msec, history or evidence of current clinically significant uncontrolled arrhythmias, history of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization, history or evidence of current > or = Class II congestive heart failure as defined by New York Heart Association, treatment refractory hypertension defined as a blood pressure of systolic> 140 mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive therapy, subjects with intra-cardiac defibrillators or permanent pacemakers.
- Known cardiac metastases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Trametinib (single tablet)
Subjects will receive, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
|
The drug substance is blended with inert
|
Experimental: Trametinib PK study (multiple tablet)
Subjects will receive on Day 1, trametinib as four tablets of 0.5 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
|
The drug substance is blended with inert
|
Experimental: Trametinib PK study (single tablet)
Subjects will receive Day 2 onwards, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
|
The drug substance is blended with inert
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Indicated Non-progressive Disease as Assessed by Investigator Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at Week 12
Time Frame: Up to Week 12
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the diameters of target lesions; Stable Disease(SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Progressive Disease(PD), At least a 20% increase in the sum of the diameters of target lesions.
Non-PD = CR + PR + SD.
|
Up to Week 12
|
Number of Participants With Indicated Non-progressive Disease as Assessed by Independent Radiologist Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at Week 12
Time Frame: Up to Week 12
|
Twelve week non-progressive disease (PD) at Week 12 was evaluated by computed tomography.
Non- PD was calculated as the sum of complete response (CR), partial response (PR), and stable disease (SD).
|
Up to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
Time Frame: until 26-Feb-2016
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or Protocol-Specific SAEs
|
until 26-Feb-2016
|
Expression of Interstitial Lung Disease Marker KL-6
Time Frame: From Baseline up to Week 36
|
Interstitial lung disease markers KL-6 assessments were carried out at Baseline (Day 1), Week 12, Week 20, Week 24, Week 28, Week 32, and Week 36
|
From Baseline up to Week 36
|
Expression of Interstitial Lung Disease Marker Surfactant Protein D
Time Frame: Baseline, Week 12, and Week 28
|
Interstitial lung disease marker Surfactant Protein D assessments were carried out at Baseline (Day 1), Week 12, and Week 28
|
Baseline, Week 12, and Week 28
|
Number of Participants With the Indicated Worst-case On-therapy Clinical Chemistry Grade Shifts From Baseline
Time Frame: From Baseline up to Week 36
|
Shift from baseline was calculated as the post baseline value minus the baseline value for albumin, alkalaine phosphatase (AP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, creatine kinase (CK), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, and phosphate.
A Worst Post Baseline (WPB) grade shift is defined as the worst change that occurred at any measured timepoint during the treatment period.
Grading was determined by the NCI Common Terminology Criteria for Adverse Events Version 3.0 (NCI-CTCAE).
Participants with missing baseline grade were designated a baseline grade of 0.
|
From Baseline up to Week 36
|
Number of Participants With the Indicated Worst-case On-therapy Coagulation Grade Shifts From Baseline
Time Frame: From Baseline up to Week 36
|
Shift from baseline was calculated as the post baseline value minus the baseline value for activated partial thromboplastin time (APTT) and prothrombin time (PT).
A Worst Post Baseline (WPB) grade shift is defined as the worst change that occurred at any measured timepoint during the treatment period.
Grading was determined by the NCI Common Terminology Criteria for Adverse Events Version 3.0 (NCI-CTCAE).
Participants with missing baseline grade were designated a baseline grade of 0.
|
From Baseline up to Week 36
|
Number of Participants With the Indicated Worst-case On-therapy Hematology Grade Shifts From Baseline
Time Frame: From Baseline up to Week 36
|
Shift from baseline was calculated as the post baseline value minus the baseline value for hemoglobin, lymphocytes, neutrophils, platelets, and leukocytes.
A Worst Post Baseline (WPB) grade shift is defined as the worst change that occurred at any measured timepoint during the treatment period.
Grading was determined by the NCI Common Terminology Criteria for Adverse Events Version 3.0 (NCI-CTCAE).
Participants with missing baseline grade were designated a baseline grade of 0.
|
From Baseline up to Week 36
|
Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Clinical Chemistry Measurements With Respect to the Normal Range
Time Frame: From Baseline up to Week 36
|
Change from baseline was calculated as the post baseline value minus the baseline value for cancer antigen 19-9 (CA 19-9), chloride, lactate dehydrogenase (LDH), and urea.
A Worst Post Baseline (WPB) change is defined as the worst change that occurred at any measured timepoint during the treatment period.
Measurements were designated as either Decreased to Low (DTL) or Increased to High (ITH) or Change to Normal/No Change (CN/NC).
Participants with missing baseline measurements or visit measurements were considered to be missing.
Participants were counted twice if the participant Decreased to Low and Increased to High.
|
From Baseline up to Week 36
|
Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Prothrombin Time Measurements With Respect to the Normal Range
Time Frame: From Baseline up to Week 36
|
Change from baseline was calculated as the post baseline value minus the baseline value for prothrombin time (PT).
A Worst Post Baseline (WPB) change is defined as the worst change that occurred at any measured timepoint during the treatment period.
Measurements were designated as either Decreased to Low (DTL) or Increased to High (ITH) or Change to Normal/No Change (CN/NC).
Participants with missing baseline measurements or visit measurements were considered to be missing.
Participants were counted twice if the participant Decreased to Low and Increased to High.
|
From Baseline up to Week 36
|
Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Hematology Measurements With Respect to the Normal Range
Time Frame: From Baseline up to Week 36
|
Change from baseline was calculated as the post baseline value minus the baseline value for basophils, eosinophils, and monocytes.
A Worst Post Baseline (WPB) change is defined as the worst change that occurred at any measured timepoint during the treatment period.
Measurements were designated as either Decreased to Low (DTL) or Increased to High (ITH) or Change to Normal/No Change (CN/NC).
Participants with missing baseline measurements or visit measurements were considered to be missing.
Participants were counted twice if the participant Decreased to Low and Increased to High.
|
From Baseline up to Week 36
|
Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Carcinoembryonic Antigen Measurements With Respect to the Normal Range
Time Frame: From Baseline up to Week 36
|
Change from baseline was calculated as the post baseline value minus the baseline value for carcinoembryonic antigen (CEA).
A Worst Post Baseline (WPB) change is defined as the worst change that occurred at any measured timepoint during the treatment period.
Measurements were designated as either Decreased to Low (DTL) or Increased to High (ITH) or Change to Normal/No Change (CN/NC).
Participants with missing baseline measurements or visit measurements were considered to be missing.
Participants were counted twice if the participant Decreased to Low and Increased to High.
|
From Baseline up to Week 36
|
Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Body Temperature
Time Frame: From Baseline up to Week 36
|
Body temperature was categorized as Decrease to <=35; Change to Normal or No Change and Increase to >=38.
Change from baseline was calculated as the post baseline value minus the baseline value.
A Worst Post Baseline (WPB) change is defined as the worst change that occurred at any measured timepoint during the treatment period.
Participants with missing baseline measurements or visit measurements were considered to be missing.
|
From Baseline up to Week 36
|
Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Blood Pressure
Time Frame: From Baseline up to Week 36
|
Systolic and diastolic blood pressure was measured after sitting for at least 5 minutes.
Systolic blood pressure (SBP) was categorized as: Grade 0 (<120), Grade 1 (>=120-<140), Grade 2 (>=140-<160) and Grade 3 (>=160).
Diastolic blood pressure (DBP) was categorized as Grade 0 (<80), Grade 1 (>=80-<90), Grade 2 (>=90-<100), and Grade 3 (>=100).
Change from baseline was calculated as the post baseline value minus the baseline value.
A Worst Post Baseline (WPB) change is defined as the worst change that occurred at any measured timepoint during the treatment period.
Participants with missing baseline measurements or visit measurements were considered to be missing.
|
From Baseline up to Week 36
|
Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Pulse Rate
Time Frame: From Baseline up to Week 36
|
Pulse rate was categorized as Decrease to <60, Change to Normal or No Change, and Increase to >100.
Change from baseline was calculated as the post baseline value minus the baseline value.
A Worst Post Baseline (WPB) change is defined as the worst change that occurred at any measured timepoint during the treatment period.
Participants with missing baseline measurements or visit measurements were considered to be missing.
|
From Baseline up to Week 36
|
Change From Baseline in Oxygen Saturation (SpO2)
Time Frame: From Baseline up to Week 36
|
Oxygen Saturation was measured at Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32 and Week 36.
For records occurring after baseline, change from baseline was calculated as the post baseline value minus the baseline value.
When either the baseline or visit value was missing, the change from baseline was considered to be missing.
|
From Baseline up to Week 36
|
Number of Participants With Progression-Free Survival as Assessed by Investigator
Time Frame: Up to Week 37
|
Progression-Free Survival (PFS) is defined as the interval of time (in weeks) between the date of randomization and the earlier of the date of disease progression and the date of death due to any cause.
Disease progression was based on the assessments by the Investigator.
If a participant received subsequent anti-cancer therapy prior to the date of documented progression or death, PFS in the participant was censored at the last adequate assessment prior the initiation of the new anti-cancer therapy.
Otherwise, if a participant did not have a documented date of progression or death, PFS in the participant was censored at the last adequate assessment.
|
Up to Week 37
|
Number of Participants With Progression-Free Survival as Assessed by Independent Radiologist
Time Frame: Up to Week 37
|
Progression-Free Survival (PFS) is defined as the interval of time (in weeks) between the date of randomization and the earlier of the date of disease progression and the date of death due to any cause.
Disease progression was based on the assessments by the independent radiologist.
If a participant received subsequent anti-cancer therapy prior to the date of documented progression or death, PFS in the participant was censored at the last adequate assessment prior the initiation of the new anti-cancer therapy.
Otherwise, if a participant did not have a documented date of progression or death, PFS in the participant was censored at the last adequate assessment.
|
Up to Week 37
|
Number of Participants With Overall Survival
Time Frame: Up to Week 39
|
Overall Survival (OS) is defined as the interval of time (in weeks) between the date of randomization and the date of death due to any cause.
For participants that did not die, time of death was censored at the date of last contact.
The date of death was taken from that recorded on the Record of Death page.
Death on study due to any cause was included.
One year OS was calculated from Kaplan-Meier estimates.
|
Up to Week 39
|
Number of Participants With Overall Response Rate as Assessed by Investigator Per RECIST 1.1 Criteria
Time Frame: Up to Week 37
|
Overall Response Rate (ORR) is defined as the number of participants achieving a confirmed CR or PR per RECIST 1.1 criteria from the start of treatment until disease progression or the start of new anti-cancer therapy.
ORR was based on responses from the Investigator assessment of best overall response, the best overall response is the best response recorded from the start of the treatment until disease progression/recurrence.
ORR is calculated as CR + PR.
|
Up to Week 37
|
Number of Participants With Overall Response Rate as Assessed by Independent Radiologist Per RECIST 1.1 Criteria
Time Frame: Up to Week 37
|
Overall Response Rate (ORR) is defined as the number of participants achieving a confirmed CR or PR per RECIST 1.1 criteria from the start of treatment until disease progression or the start of new anti-cancer therapy.
ORR was based on responses from the Independent Radiologist assessment of best overall response, the best overall response is the best response recorded from the start of the treatment until disease progression/recurrence.
ORR is calculated as CR + PR.
|
Up to Week 37
|
Number of Participants With Investigator-Assessed Time to Response
Time Frame: Up to Week 37
|
Time to response (TTR) event was defined as achievement of a confirmed CR or PR, as the time from date of randomization until date of first documented evidence of CR or PR (whichever status is recorded first).
If a participant received subsequent anti-cancer therapy prior to the date of documented progression or death, progression free survival (PFS) in the participant was censored at the last adequate assessment prior the initiation of the new anti-cancer therapy.
Otherwise, if a participant did not have a documented date of progression or death, PFS in the participant was censored at the last adequate assessment.
|
Up to Week 37
|
Number of Weeks Until Time to Response Assessed With Independent Radiologist
Time Frame: Up to Week 37
|
Time to response (TTR) event was defined as achievement of a confirmed CR or PR, as the time from date of randomization until date of first documented evidence of CR or PR (whichever status is recorded first).
If a participant received subsequent anti-cancer therapy prior to the date of documented progression or death, progression free survival (PFS) in the participant was censored at the last adequate assessment prior the initiation of the new anti-cancer therapy.
Otherwise, if a participant did not have a documented date of progression or death, PFS in the participant was censored at the last adequate assessment.
Only 1 participant reached PR therefore estimated time to response cannot be presented.
The time to response for this patient is presented as the actual number of weeks to PR.
|
Up to Week 37
|
Number of Participants With Investigator-Assessed Duration of Response
Time Frame: Up to Week 37
|
Duration of response was summarized for participants with a confirmed CR or PR and is defined as the time (in weeks) from the initial response (CR/PR) to first documented disease progression or death due to any cause.
If a participant received subsequent anti-cancer therapy prior to the date of documented progression or death, PFS in the participant was censored at the last adequate assessment prior the initiation of the new anti-cancer therapy.
Otherwise, if a participant did not have a documented date of progression or death, PFS in the participant was censored at the last adequate assessment.
|
Up to Week 37
|
Number of Participants With Independent Radiologist Assessed Duration of Response
Time Frame: Up to Week 37
|
Duration of response was summarized for participants with a confirmed CR or PR and is defined as the time (in weeks) from the initial response (CR/PR) to first documented disease progression or death due to any cause.
If a participant received subsequent anti-cancer therapy prior to the date of documented progression or death, PFS in the participant was censored at the last adequate assessment prior the initiation of the new anti-cancer therapy.
Otherwise, if a participant did not have a documented date of progression or death, PFS in the participant was censored at the last adequate assessment.
|
Up to Week 37
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 117134
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Trametinib (single tablet)
-
GlaxoSmithKlineCompleted
-
Stanford UniversityBoston Children's HospitalRecruitingArterial Disease | Venous MalformationUnited States
-
PfizerCompleted
-
University Health Network, TorontoNot yet recruitingArteriovenous Malformations
-
PfizerArvinas Estrogen Receptor, Inc.Recruiting
-
BayerCompletedRenal Impairment | Chronic Kidney Disease | Healthy VolunteersGermany
-
PfizerRecruitingHealthy ParticipantsUnited States
-
Melanoma Institute AustraliaNovartisRecruiting
-
The HIV Netherlands Australia Thailand Research...Police General Hospital; Faculty of Medical Sciences, Radboud University of... and other collaboratorsCompleted
-
Memorial Sloan Kettering Cancer CenterCompletedNon Small Cell Lung Cancer | KRAS Gene MutationUnited States